Price Alert

Stereotaxis Inc. (STXS)

AMEX: STXS · Real-Time Price · USD

2.87

0.09 (3.24%)

At close: Aug 19, 2025, 3:59 PM

2.95

2.97%

After-hours: Aug 19, 2025, 07:55 PM EDT

3.24% (1D)

Bid	2.95
Market Cap	259.23M
Revenue (ttm)	27.51M
Net Income (ttm)	-25.68M
EPS (ttm)	-0.29
PE Ratio (ttm)	-9.88
Forward PE	-14.59
Analyst	n/a

Ask	2.95
Volume	1,195,952
Avg. Volume (20D)	444,870
Open	2.95
Previous Close	2.78
Day's Range	2.85 - 3.05
52-Week Range	1.54 - 3.05
Beta	1.51

About STXS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol STXS

Website n/a

Full Company Profile

Next Earnings Release

Stereotaxis Inc. is scheduled to release its earnings on Nov 10, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

+15.11%

Stereotaxis shares are trading higher after the co... Unlock content with Pro Subscription

1 month ago

-0.42%

Stereotaxis shares are trading lower after the company announced a $12.5 million registered direct offering.

News

1 week ago · seekingalpha.com

Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript

Stereotaxis, Inc. (NYSE:STXS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David Leo Fischel - CEO & Chairman Kimberly R. Peery - Chief Financial Officer Conference...

1 week ago · zacks.com

Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.07 per share a year ago.

2 weeks ago · zacks.com

Will Stereotaxis Inc. (STXS) Report Negative Earnings Next Week? What You Should Know

Stereotaxis (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial

STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.

1 month ago · seekingalpha.com

Stereotaxis: Recurring Revenue Inflection

I rate Stereotaxis Strong Buy, with 85% upside to $4 PT, driven by underappreciated recurring revenue and regulatory catalysts. Recurring revenue is inflecting above 25% growth, with high-margin dispo...